Registro de fonte primária
Nível de decisãoResultados topline
Quince Therapeutics: Leitura dos dados principais do Fase 3 NEAT para eDSP em A-T esperada no T1 2026
A empresa concluiu o recrutamento do ensaio pivotal Fase 3 NEAT (105 participantes no total) e confirmou que os resultados principais serão divulgados no T1 2026. O ensaio permanece sob uma Avaliação Especial de Protocolo da FDA, e dados positivos apoiariam uma submissão de NDA planejada para o 2S 2026.
Fatos principais
Trecho da fonte
EX-99.1 2 qncx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results Pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T remains on track with topline results expected in first quarter of 2026 SOUTH SAN FRANCISCO, Calif. – November 12, 2025 – Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the third quarter ended September 30, 2025. Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, “Quince remains on track to report